Rogers Corporation - SIC # 3673 -

Ticker Exchange SIC # Website Latest Ticker
ROG New York 3673 www.rogerscorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rogers Corporation

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD) - Sep 21st, 2026 9:45 am
3 Low-Volatility Stocks We Find Risky - Sep 21st, 2026 1:42 am
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis - Sep 18th, 2026 4:45 am
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases - Sep 17th, 2026 12:30 pm
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study - Sep 16th, 2026 11:00 pm
1 Cash-Heavy Stock with Competitive Advantages and 2 That Underwhelm - Sep 16th, 2026 1:55 am
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm - Sep 15th, 2026 3:40 am
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer - Sep 12th, 2026 6:00 pm
3 Profitable Stocks We Keep Off Our Radar - Sep 10th, 2026 5:13 pm
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments - Sep 9th, 2026 11:00 pm
Electronic Components & Manufacturing Stocks Q2 Results: Benchmarking Rogers (NYSE:ROG) - Sep 9th, 2026 4:42 pm
Rogers Corporation Announces Investor Day on September 30, 2026 - Sep 9th, 2026 2:38 pm
2 Services Stocks to Research Further and 1 We Turn Down - Sep 4th, 2026 6:30 am
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) - Aug 28th, 2026 1:00 am
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA - Aug 26th, 2026 12:52 pm
Rogers Corp. (ROG) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Aug 24th, 2026 7:55 am
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States - Aug 20th, 2026 9:45 am
How Much Upside is Left in Rogers Corp. (ROG)? Wall Street Analysts Think 25.08% - Aug 13th, 2026 7:55 am
Rogers (ROG) Rebounds On Earnings And Guidance As Investors Weigh The Valuation Case - Aug 11th, 2026 4:15 pm
Is Rogers (ROG) Stock Too Pricey For Its Earnings? - Aug 11th, 2026 2:10 am